Evidence map›Paper›PMID 28430585›Full record

ArticleOncotarget2017

FOXD3 regulates anaplastic thyroid cancer progression.

Huabin Yin, Tong Meng, Lei Zhou, Feixing Zhao, Xiufang Li, Yundong Li, Mengjun Hu, Haiyan Chen, Dianwen Song

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Huabin YinDepartment of Orthopedics, Shanghai Bone Tumor Institute, Shanghai General Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PR China.
Tong MengDepartment of Orthopedics, Shanghai Bone Tumor Institute, Shanghai General Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PR China.
Lei ZhouDepartment of Orthopedic Oncology, Changzheng Hospital, The Second Military Medical University, Shanghai, PR China.
Feixing ZhaoZhuji People's Hospital of Zhejiang Province, Zhuji, Zhejiang, PR China.
Xiufang LiZhuji People's Hospital of Zhejiang Province, Zhuji, Zhejiang, PR China.
Yundong LiDepartment of General Surgery, Haiyang People's Hospital, Haiyang Shangdong, PR China.
Mengjun HuZhuji People's Hospital of Zhejiang Province, Zhuji, Zhejiang, PR China.
Haiyan ChenDepartment of Rheumatology, Shanghai Guanghua Hospital of Integrated Traditional and Western Medicine, Shanghai, China.
Dianwen SongDepartment of Orthopedics, Shanghai Bone Tumor Institute, Shanghai General Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, PR China.
Shanghai First People's Hospital · CNZhuhai People's Hospital · CNSecond Military Medical University · CNShanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anaplastic thyroid cancer (ATC) is an aggressive malignancy with poor prognosis. It was reported that Forkhead box D3 (FOXD3) transcription factor is associated with several cancers. We investigated its antitumorigenic role of ATC in this study. The ATC cell lines SW1736 and K18 exhibited lower FOXD3 expression than the Nthy-ori-3-1 normal thyroid cell line. FOXD3 downregulation in ATC cell lines promoted invasiveness and epithelial-to-mesenchymal transition (EMT) and decreased cellular apoptosis. FOXD3 silencing also enhanced p-ERK levels in the ATC cell lines, suggesting it negatively regulated MAPK/ERK signaling. Silencing FOXD3 in SW1736 cells also led to generation of larger xenograft tumors with high p-ERK and low E-cadherin levels. Moreover, human ATC samples showed lower FOXD3 and higher p-ERK levels than samples of normal thyroid tissue. These findings demonstrate that FOXD3 acts as a tumor suppressor during anaplastic thyroid carcinogenesis and highlight its potential for clinical application.

Indexed as

Biomarkers, TumorAnimalsApoptosisCell Line, TumorCell ProliferationCell SurvivalDisease Models, AnimalDisease ProgressionEpithelial-Mesenchymal TransitionFemaleForkhead Transcription FactorsGene ExpressionGene Knockdown TechniquesHeterograftsHumansMAP Kinase Signaling SystemBiomarkers, TumorForkhead Transcription FactorsFOXD3 protein, humanFOXD3human anaplastic thyroid cancerMAPK/ERK signal pathwaymetastasis

Identifiers

PMID28430585
PMCPMC5464897
OpenAlexW2604658854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.